机构:[1]Royal Perth Hosp, Dept Neurol, Stroke Unit, Perth, WA 6000, Australia;[2]Prince Wales Hosp, Shatin, Hong Kong, Peoples R China;[3]Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China;[4]Chiang Mai Univ, No Neurosci Ctr, Chiang Mai 50000, Thailand;[5]Maharaj Nakorn Chiang Mai Hosp, Chiang Mai, Thailand;[6]Natl Univ Singapore, Dept Pharmacol, Singapore 117548, Singapore;[7]Cent Coast Neurosci Res Grp, Gosford, NSW, Australia;[8]Alfred Hosp, Melbourne, Vic, Australia;[9]Asan Med Ctr, Seoul, South Korea;[10]Univ Ulsan, Coll Med, Seoul, South Korea;[11]Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai 200030, Peoples R China;[12]Chang Gung Univ, Chang Gung Mem Hosp, Coll Med, Kaohsiung, Taiwan;[13]Prince Court Med Ctr, Kuala Lumpur, Malaysia;[14]Univ Indonesia, Fac Med, Dept Neurol, Jakarta, Indonesia;[15]Philippine Heart Ctr, Quezon City, Philippines;[16]Univ Santo Tomas, Quezon City, Philippines;[17]Tachikawa Hosp, Federat Nat Publ Serv Personnel Mutual Aid Assoc, Tokyo, Japan;[18]Capital Med Univ, Beijing Tiantan Hosp, Beijing, Peoples R China;首都医科大学附属天坛医院[19]Seoul Natl Univ Hosp, Seoul 110744, South Korea;[20]Royal Perth Hosp, Dept Neurol, Stroke Unit, 197 Wellington St, Perth, WA 6000, Australia
Stroke is a major cause of morbidity and mortality in Asia, and its pattern is changing. The incidence of haemorrhagic stroke is declining while the incidence of ischaemic stroke caused by large artery atherothromboembolism is increasing secondary to an increase in the prevalence of hypercholesterolaemia. The Working Group on Stroke and Lipids Management in Asia Consensus Panel assembled leading experts from the region to reach a consensus on how to address this challenge. The group discussed the observational epidemiology of the relationship between cholesterol and risk of stroke, the clinical trial evidence base for cholesterol-lowering for stroke prevention, and issues specific to stroke and lipid management for Asian doctors and patients. Stroke guidelines from many of the Asian countries have recently recommended consideration of statins for recurrent stroke prevention in patients with previous ischaemic stroke or transient ischaemic attack. However, because these recommendations have yet to be implemented widely, there is a need to educate Asian physicians and patients about the importance of adequate control of hypercholesterolaemia. Further trials of statins in Asian patients are also needed, particularly in those with intracranial stenosis.
基金:
Biomedical Research CouncilAgency for Science Technology & Research (ASTAR); Boehringer-Ingelheim GmbHBoehringer Ingelheim; Eisai Inc.Eisai Inc; Les Laboratoires Servier; Moleac Pte Ltd.; National Medical Research Council, SingaporeNational Medical Research Council, Singapore; National Research Foundation; Novartis AG; sanofi-aventisSanofi-Aventis; UCB S. AUCB Pharma SA
第一作者机构:[1]Royal Perth Hosp, Dept Neurol, Stroke Unit, Perth, WA 6000, Australia;
通讯作者:
通讯机构:[1]Royal Perth Hosp, Dept Neurol, Stroke Unit, Perth, WA 6000, Australia;[20]Royal Perth Hosp, Dept Neurol, Stroke Unit, 197 Wellington St, Perth, WA 6000, Australia
推荐引用方式(GB/T 7714):
Hankey Graeme J.,Wong Ka S. L.,Chankrachang Siwaporn,et al.Management of cholesterol to reduce the burden of stroke in Asia: consensus statement[J].INTERNATIONAL JOURNAL OF STROKE.2010,5(3):209-216.doi:10.1111/j.1747-4949.2010.00429.x.
APA:
Hankey, Graeme J.,Wong, Ka S. L.,Chankrachang, Siwaporn,Chen, Christopher,Crimmins, Denis...&Yoon, Byung-Woo.(2010).Management of cholesterol to reduce the burden of stroke in Asia: consensus statement.INTERNATIONAL JOURNAL OF STROKE,5,(3)
MLA:
Hankey, Graeme J.,et al."Management of cholesterol to reduce the burden of stroke in Asia: consensus statement".INTERNATIONAL JOURNAL OF STROKE 5..3(2010):209-216